Levosimendan improves event free survival by 50% in end-stage heart failure, Third generation MRA shows improved potassium and kidney tolerance in heart failure patients with CKD

Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep study.  In a second study, the third generation mineralocorticoid receptor antagonist (MRA) BAY 94-8862 showed improved potassium and kidney tolerance in heart failure patients with chronic kidney disease (CKD).  Read more Topics: Heart Failure (HF)
Source: ESC News and Press - Category: Cardiology Source Type: news